Antibodies News and Research RSS Feed - Antibodies News and Research

Malaria parasites use complement system to evade human immune response, study finds

Malaria parasites use complement system to evade human immune response, study finds

The malaria parasite Plasmodium falciparum hijacks an immune system process to invade red blood cells, according to a study led by researchers at Penn State College of Medicine. Understanding how malaria invades the cells could lead to a more effective vaccine. [More]
Japanese scientists find evidence that cytokine IL-17A plays crucial role in psoriasis

Japanese scientists find evidence that cytokine IL-17A plays crucial role in psoriasis

Psoriasis is an inflammatory skin condition that affects some 125 million people worldwide. It is characterized by itchy, scaly skin plaques. The exact cause of psoriasis is unclear. [More]
Novel strategy to predict antigenic evolution of circulating influenza viruses

Novel strategy to predict antigenic evolution of circulating influenza viruses

During the 2014-15 flu season, the poor match between the virus used to make the world's vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective. [More]
Nanoparticles of ultrapure silicon act as luminescent markers in early diagnosis of cancer

Nanoparticles of ultrapure silicon act as luminescent markers in early diagnosis of cancer

The group of Russian and French researchers, with the participation of scientists from the Lomonosov Moscow State University, has succeeded to synthesize nanoparticles of ultrapure silicon, which exhibited the property of efficient photoluminescence, i.e., secondary light emission after photoexcitation. [More]
Phase I study of triple drug combination shows promise in multiple myeloma patients

Phase I study of triple drug combination shows promise in multiple myeloma patients

PharmaMar announces the positive results from a Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. [More]
Research provides pathway toward creation of first broad-spectrum antiviral drug

Research provides pathway toward creation of first broad-spectrum antiviral drug

By studying the rare person -- about one in a million -- who can fight off viral infections more effectively than everyone else, investigators at the Icahn School of Medicine at Mount Sinai have developed a strategy to help the rest of us achieve this enhanced anti-viral state. [More]
Researchers identify hCRTh2 protein as possible therapeutic target for asthma

Researchers identify hCRTh2 protein as possible therapeutic target for asthma

Patients with asthma have chronic lung inflammation that results in sporadic narrowing of the airways and difficulty breathing. Symptoms and severity are variable among individuals; however, the cells and inflammatory factors that trigger asthmatic events have been fairly well characterized and are similar regardless of the asthma-inducing stimuli. [More]
Understanding antibody transport mechanisms in the brain

Understanding antibody transport mechanisms in the brain

Diseases of the central nervous system (CNS), such as stroke, brain cancer, and Alzheimer's disease, are a serious threat affecting over 50 million Americans with an associated cost of over $750 billion per year, which is expected to grow significantly over the coming decades. [More]
Landmark study characterizes evolution of symptoms, signs of acute HIV infection

Landmark study characterizes evolution of symptoms, signs of acute HIV infection

Acute HIV infection (AHI) contributes significantly to HIV transmission and may be important for intervention strategies seeking to reduce incidence and achieve a functional cure. [More]
ProBioGen will license GlymaxX® to Thermo Fisher Scientific for use in developing allergy diagnostics

ProBioGen will license GlymaxX® to Thermo Fisher Scientific for use in developing allergy diagnostics

ProBioGen, a leading specialist for contract development and manufacturing of complex glycoproteins and corresponding technologies, today announced that Thermo Fisher Scientific has licensed its GlymaxX® technology for use in development of allergy diagnostics. [More]
Research on immune system sets stage for novel approach to cancer immunotherapy

Research on immune system sets stage for novel approach to cancer immunotherapy

Basic research into the dual nature of certain immune system cells has set the stage for a new approach to cancer immunotherapy that avoids some of the shortcomings associated with other methods, scientists at Dana-Farber Cancer Institute report in a new study in the Proceedings of the National Academy of Sciences. [More]
Unlocking the dark proteome: an interview with Dr Kriwacki

Unlocking the dark proteome: an interview with Dr Kriwacki

The term dark proteome refers to proteins whose structural features and thus functions are not well understood. Many proteins within the dark proteome do not fold into stable three-dimensional structures. These proteins are called intrinsically disordered proteins (IDPs) and feature highly flexible, disordered confirmations. [More]
New optimised PCR tests for reliable diagnosis of Zika virus

New optimised PCR tests for reliable diagnosis of Zika virus

DZIF scientists from the University of Bonn have shown that not all conventional Zika virus molecular diagnostic tests for are sufficiently reliable. They developed optimised assays and a control for quantifying viruses in blood and urine. [More]
Researchers investigate effects of non-allergenic components of pollen on allergy sufferers

Researchers investigate effects of non-allergenic components of pollen on allergy sufferers

Up to now, research into pollen allergies has largely focused on allergens - those components of pollen that trigger hypersensitivity reactions. When it comes into contact with the nasal mucous membrane, however, pollen releases a host of other substances in addition to allergens. [More]
Potential vaccine that resembles sugar structures may help fight against gut bacterium C. difficile

Potential vaccine that resembles sugar structures may help fight against gut bacterium C. difficile

A vaccine against one of the most dangerous hospital germs may soon be available. Scientists from the Max Planck Institute of Colloids and Interfaces in Potsdam and the Freie Universität Berlin have developed a substance that elicits an immune response against the gut bacterium Clostridium difficile. [More]
Tdap vaccine safe for mothers and infants

Tdap vaccine safe for mothers and infants

Tetanus-diphtheria-acellular pertussis (Tdap) vaccine is recommended for all pregnant women in the U.S. as the key medical intervention to protect newborn infants from pertussis (whooping cough). [More]
Mouse models of Zika virus infection in pregnancy provide basis to develop vaccines, treatments

Mouse models of Zika virus infection in pregnancy provide basis to develop vaccines, treatments

Two mouse models of Zika virus infection in pregnancy have been developed by a team of researchers at Washington University School of Medicine in St. Louis. In them, the virus migrated from the pregnant mouse's bloodstream into the placenta, where it multiplied, then spread into the fetal circulation and infected the brains of the developing pups. [More]
Patient-specific immunotherapeutic vaccines may improve overall survival of melanoma patients

Patient-specific immunotherapeutic vaccines may improve overall survival of melanoma patients

Two patients with melanoma that had spread to the liver survived for at least 8.5 and 12 years after resection of the hepatic tumor and treatment with patient-specific immunotherapeutic vaccines. [More]
New study sheds more light on level of alcohol consumption among people with hepatitis C

New study sheds more light on level of alcohol consumption among people with hepatitis C

Drinking alcohol can increase the risk of illness and death from the hepatitis C virus. A new national household study of U.S. adults published in the American Journal of Preventive Medicine shows that many people living with hepatitis C report either former or current excessive alcohol use. [More]
Experimental vaccine protects healthy U.S. adults from malaria infection for more than one year

Experimental vaccine protects healthy U.S. adults from malaria infection for more than one year

An experimental malaria vaccine protected a small number of healthy, malaria-naïve adults in the United States from infection for more than one year after immunization, according to results from a Phase 1 trial described in the May 9th issue of Nature Medicine. [More]
Advertisement
Advertisement